Matches in Wikidata for { <http://www.wikidata.org/entity/Q92049380> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q92049380 description "article scientifique publié en 2019" @default.
- Q92049380 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q92049380 description "scientific article published on 05 July 2019" @default.
- Q92049380 description "wetenschappelijk artikel" @default.
- Q92049380 description "наукова стаття, опублікована 5 липня 2019" @default.
- Q92049380 name "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 name "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 type Item @default.
- Q92049380 label "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 label "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 prefLabel "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 prefLabel "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 P1433 Q92049380-397273E8-7A24-4ABF-8BC4-7B26025D3116 @default.
- Q92049380 P1476 Q92049380-68B3CB43-28A6-4DAD-BB4A-B2DE6879983E @default.
- Q92049380 P2093 Q92049380-0655D223-6AF5-45F3-BFCA-234DAE936F73 @default.
- Q92049380 P2093 Q92049380-1E4CE93B-D08C-4FDD-99F1-A192A86C2839 @default.
- Q92049380 P2093 Q92049380-223FFDEF-2EA4-480C-BCA9-75C79363B857 @default.
- Q92049380 P2093 Q92049380-7D5A946A-F9E2-4188-957E-6A71C4973588 @default.
- Q92049380 P2093 Q92049380-7FB09ED1-7A8C-4318-AB21-D8F93D734F08 @default.
- Q92049380 P2093 Q92049380-82EC6A58-8CD7-4846-B03F-C5BEFBC0D533 @default.
- Q92049380 P2093 Q92049380-A5CCE3E8-E045-466D-A2F2-05995DA34FC2 @default.
- Q92049380 P2093 Q92049380-B21948CA-5C8C-4D8B-AB89-85B8EA1A068A @default.
- Q92049380 P2093 Q92049380-C9E8096F-4AF6-4E95-8FE8-11A9159EA46E @default.
- Q92049380 P2093 Q92049380-F704E3BD-C7BC-4154-B6BF-FC28B7D8E15E @default.
- Q92049380 P304 Q92049380-BB0406C7-3C2F-47A7-8D93-905B6B165D8A @default.
- Q92049380 P31 Q92049380-251845D3-8156-4692-AC6E-E2CC9D4ACB13 @default.
- Q92049380 P356 Q92049380-172D362D-F81C-4F98-8686-941A66FF9BF5 @default.
- Q92049380 P478 Q92049380-B3C9AECA-5109-4A4F-918A-7BB59E7D060A @default.
- Q92049380 P50 Q92049380-608678C0-C6BF-4738-9D5F-04419E4A9F1F @default.
- Q92049380 P577 Q92049380-A840569B-C18D-407D-B2F3-D62E9918BFA9 @default.
- Q92049380 P698 Q92049380-482589E7-B611-4941-8E70-62FD0A05076E @default.
- Q92049380 P921 Q92049380-3B7C2FA6-97ED-4275-A1D9-ACA800C220CC @default.
- Q92049380 P921 Q92049380-40AA336C-9433-410B-A3B2-E5A913B9C0DE @default.
- Q92049380 P921 Q92049380-9D04EB3B-17CA-43ED-8FC6-94A7AA37EBD6 @default.
- Q92049380 P356 J.ATHEROSCLEROSIS.2019.07.007 @default.
- Q92049380 P698 31326727 @default.
- Q92049380 P1433 Q4813570 @default.
- Q92049380 P1476 "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial" @default.
- Q92049380 P2093 "Ahmad Sajadieh" @default.
- Q92049380 P2093 "Amirsalar Samkani" @default.
- Q92049380 P2093 "Christian Anholm" @default.
- Q92049380 P2093 "Lene Rørholm Pedersen" @default.
- Q92049380 P2093 "Mogens Fenger" @default.
- Q92049380 P2093 "Olav Wendelboe Nielsen" @default.
- Q92049380 P2093 "Ole Peter Kristiansen" @default.
- Q92049380 P2093 "Preman Kumarathurai" @default.
- Q92049380 P2093 "Steen Bendix Haugaard" @default.
- Q92049380 P2093 "Sten Madsbad" @default.
- Q92049380 P304 "60-66" @default.
- Q92049380 P31 Q13442814 @default.
- Q92049380 P356 "10.1016/J.ATHEROSCLEROSIS.2019.07.007" @default.
- Q92049380 P478 "288" @default.
- Q92049380 P50 Q90614368 @default.
- Q92049380 P577 "2019-07-05T00:00:00Z" @default.
- Q92049380 P698 "31326727" @default.
- Q92049380 P921 Q19484 @default.
- Q92049380 P921 Q3025883 @default.
- Q92049380 P921 Q844935 @default.